Literature DB >> 26682925

DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model.

Koichi Achiwa1, Masatoshi Ishigami2, Yoji Ishizu1, Teiji Kuzuya1, Takashi Honda1, Kazuhiko Hayashi1, Yoshiki Hirooka1, Yoshiaki Katano3, Hidemi Goto1.   

Abstract

Nonalcoholic steatohepatitis (NASH) patients progress to liver cirrhosis and even hepatocellular carcinoma (HCC). Several lines of evidence indicate that accumulation of lipopolysaccharide (LPS) and disruption of gut microbiota play contributory roles in HCC. Moreover, in a dextran sodium sulfate (DSS)-induced colitis model in mice, a high-fat diet increases portal LPS level and promotes hepatic inflammation and fibrosis. However, this diet-induced NASH model requires at least 50 weeks for carcinogenesis. In this study, we sought to determine whether increased intestinal permeability would aggravate liver inflammation and fibrosis and accelerate tumorigenesis in a diet-induced NASH model. Mice were fed a choline-deficient high-fat (CDHF) diet for 4 or 12 weeks. The DSS group was fed CDHF and intermittently received 1% DSS in the drinking water. Exposure to DSS promoted mucosal changes such as crypt loss and increased the number of inflammatory cells in the colon. In the DSS group, portal LPS levels were elevated at 4 weeks, and the proportions of Clostridium cluster XI in the fecal microbiota were elevated. In addition, levels of serum transaminase, number of lobular inflammatory cells, F4/80 staining-positive area, and levels of inflammatory cytokines were all elevated in the DSS group. Liver histology in the DSS group revealed severe fibrosis at 12 weeks. Liver tumors were detected in the DSS group at 12 weeks, but not in the other groups. Thus, DSS administration promoted liver tumors in a CDHF diet-induced NASH mouse over the short term, suggesting that the induction of intestinal inflammation and gut disruption of microbiota in NASH promote hepatic tumorigenesis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Choline-deficient high-fat; Colitis; Fibrosis; Nonalcoholic steatohepatitis; Tumorigenesis

Mesh:

Substances:

Year:  2015        PMID: 26682925     DOI: 10.1016/j.bbrc.2015.12.012

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Intestinal fibrosis: ready to be reversed.

Authors:  Giovanni Latella; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

2.  Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model.

Authors:  Norihiro Imai; Michitaka Suzuki; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Masatoshi Ishigami; Yoshiki Hirooka; Tetsuya Ishikawa; Hidemi Goto; Toyoshi Fujimoto
Journal:  Histochem Cell Biol       Date:  2017-04-18       Impact factor: 4.304

Review 3.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 4.  The gut microbiome and liver cancer: mechanisms and clinical translation.

Authors:  Le-Xing Yu; Robert F Schwabe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-07-05       Impact factor: 46.802

5.  Profiling of tumour-associated microbiota in human hepatocellular carcinoma.

Authors:  Seiga Komiyama; Takahiro Yamada; Nobuyuki Takemura; Norihiro Kokudo; Koji Hase; Yuki I Kawamura
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

6.  Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice.

Authors:  Shoji Yamada; Yoko Takashina; Mitsuhiro Watanabe; Ryogo Nagamine; Yoshimasa Saito; Nobuhiko Kamada; Hidetsugu Saito
Journal:  Oncotarget       Date:  2018-01-06

Review 7.  Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites.

Authors:  Andrea Verdugo-Meza; Jiayu Ye; Hansika Dadlani; Sanjoy Ghosh; Deanna L Gibson
Journal:  Nutrients       Date:  2020-05-15       Impact factor: 5.717

8.  Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation.

Authors:  Yusuke Imai; Osamu Yoshida; Takao Watanabe; Atsushi Yukimoto; Yohei Koizumi; Yoshio Ikeda; Yoshio Tokumoto; Masashi Hirooka; Masanori Abe; Yoichi Hiasa
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 9.  Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management.

Authors:  Jinghang Xu; Qiao Zhan; Yanan Fan; Emily Kwun Kwan Lo; Fangfei Zhang; Yanyan Yu; Hani El-Nezami; Zheng Zeng
Journal:  Pathogens       Date:  2021-06-22

10.  Gut-Liver Axis: Liver Sinusoidal Endothelial Cells Function as the Hepatic Barrier in Colitis-Induced Liver Injury.

Authors:  Yang Wang; Yifan Zhang; Yun Liu; Jun Xu; Yulan Liu
Journal:  Front Cell Dev Biol       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.